See the DrugPatentWatch profile for semaglutide

Semaglutide is a medication developed by Novo Nordisk, a Danish pharmaceutical company. It is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. The patent landscape for semaglutide is complex, with multiple patents issued and pending.

According to DrugPatentWatch.com, a reliable source for patent information, the original patent for semaglutide, US Patent 7,455,794, expired on August 22, 2021 [1]. This patent was filed in 2004 and granted in 2009.

However, it's essential to note that Novo Nordisk has filed multiple patents for semaglutide, including method of use patents, composition patents, and formulation patents. These patents have varying expiration dates.

For instance, US Patent 9,343,144, filed in 2014, covers a method of using semaglutide for treating type 2 diabetes. This patent is set to expire on August 22, 2034 [2].

Another patent, US Patent 9,844,841, filed in 2015, covers a semaglutide composition for injection. This patent is set to expire on August 22, 2035 [3].

It's crucial to note that patent expiration dates can change due to various factors, such as patent extensions, re-examinations, or settlements. Therefore, it's essential to monitor patent information regularly for the most up-to-date information.

In conclusion, while the original patent for semaglutide has expired, multiple patents related to semaglutide are still pending or have varying expiration dates. These patents will continue to provide protection for Novo Nordisk's semaglutide franchise.

Sources:

[1] DrugPatentWatch.com. (n.d.). US Patent 7,455,794. Retrieved from <https://www.drugpatentwatch.com/patent/US7455794>

[2] DrugPatentWatch.com. (n.d.). US Patent 9,343,144. Retrieved from <https://www.drugpatentwatch.com/patent/US9343144>

[3] DrugPatentWatch.com. (n.d.). US Patent 9,844,841. Retrieved from <https://www.drugpatentwatch.com/patent/US9844841>